Table 4 CSF and plasma-based inflammatory biomarker analysis

From: A Phase IIa clinical trial to evaluate the effects of anti-retroviral therapy in Alzheimer’s disease (ART-AD)

CSF

PLASMA

PROTEIN

POST-PRE (IQR)

P VALUE

PROTEIN

POST-PRE (IQR)

P VALUE

bFGF

NA

NA

bFGF

0.6377 (−1.97, 1.02)

>0.9999

CRP

39.06 (-7246, 1342)

>0.9999

CRP

−903927 (−2106270, 118451)

0.063

Eotaxin

NA

NA

Eotaxin

210.8 (39.0, 439)

0.092

Eotaxin-3

NA

NA

Eotaxin-3

3.271 (−1.88, 7.34)

0.398

Flt1

−6.977 (−14.0, 1.15)

0.050

Flt-1

−1.081 (−7.16, 1.57)

0.380

IFN-g

NA

NA

IFN-g

0.9857 (-0.233, 1.46)

0.206

IL-1a

NA

NA

IL-1a

NA

NA

IL-1b

NA

NA

IL-1b

NA

NA

IL-2

NA

NA

IL-2

NA

NA

IL-4

NA

NA

IL-4

NA

ND

IL-5

−0.03144 (-0.119, 0.454)

0.298

IL-5

−0.01947 (−0.169, 0.0651)

0.718

IL-6

−0.06009 (−0.0209, 0.0595)

0.364

IL-6

−0.04436 (−0.866, 0.275)

0.622

IL-7

−0.01858 (−0.0544, 0.0745)

0.576

IL-7

0.1686 (−1.61, 0.441)

0.311

IL-8

−1.844 (−5.63, 2.45)

0.377

IL-8

0.5924 (−1.21, 17.9)

0.677

IL-10

NA

NA

IL-10

0.04822 (−0.0142, 0.0854)

0.064

IL-12_

  

IL-12_

  

IL-23p40

0.1495 (−0.576, 0.459)

>0.9999

IL23p40

−0.5283 (−34.3, 31.2)

0.967

IL-13

NA

NA

IL-13

NA

NA

I-15

0.09699 (−0.284, 0.345)

0.652

IL-15

0.2861 (0.150, 0.456)

***0.006

IL-16

0.1714 (−0.284, 0.449)

0.719

IL-16

0.9511 (−10.1, 10.6)

0.860

IL-17a

−0.002132 (−0.0867, 0.0664)

0.956

IL-17A

−0.04166 (−0.141, 0.0588)

0.417

IP-10

12.55 (−82.4, 40.3)

0.910

IP-10

30.29 (−46.4, 61.2)

0.470

MCP-1

21.2 (5.33, 34.7)

0.076

MCP1

15.5 (−18.1, 52.1)

0.208

MCP-4

−0.006317 (−0.0945, 0.140)

0.884

MCP4

47.17 (−31.7, 82.5)

0.155

MDC

NA

NA

MDC

−14.69 (−44.7, 86.7)

>0.9999

MIP-1a

NA

NA

MIP-1a

1.421 (−0.391, 3.30)

0.279

MIP-1b

−0.6947 (−2.51, 1.42)

0.383

MIP-1b

−0.2869 (−18.2, 8.90)

0.6772

PIGF

−0.7235 (−1.71, 0.180)

0.118

PIGF

−0.05237 (−0.919, 0.942)

0.883

SAA

−72.3 (−394, 4.49)

0.055

SAA

−109699 (−1116509, 173190)

0.340

siCAM

219.8 (−112, 480)

0.165

siCAM

−10037 (−67421, 46858)

0.605

svCAM

−57.57 (−647, 638)

0.857

svCAM

8605 (−46964, 50495)

0.721

TARC

−0.157 (−0.509, 0.121)

0.257

TARC

3.749 (−12.8, 10.4)

0.850

Tie-2

NA

NA

Tie-2

−123.3 (−623, 257)

0.331

TNF-a

NA

NA

TNF-a

0.006858 (−0.102, 0.201)

0.791

TNF-b

NA

NA

TNF-b

NA

NA

VEGF-A

0.08938 (−0.0830, 0.355)

0.203

VEGF-A

0.1319 (−1.01, 1.36)

0.850

VEGF-C

−8.791 (−28.8, 7.79)

0.192

VEGF-C

2.184 (−70.6, 49.5)

0.791

VEGF-D

−3.987 (−9.22, 3.48)

0.199

VEGF-D

81.78 (−88.2, 245)

0.250

  1. A value of “NA” is included for targets in which three or more participants had undetectable values or %CV values exceeding 15. POST-PRE values are in pg/ml. CSF, N = 9; Plasma, N = 12. Normality testing was based on the POST-PRE difference for each target; P values are based on two-sided paired sample t-test (normal distribution) or Wilcoxon matched-pairs signed rank test (non-normal distribution). IQR Interquartile Range.